Alchem Laboratories

Alchem Laboratories is a long-established, private biotech firm with a dual focus on infectious disease therapeutics and a robust contract development and manufacturing (CDMO) service for clinical-stage APIs. Its core capabilities include custom synthesis, assay development, and high-throughput screening (HTS), supported by leadership with deep experience in drug delivery and government contracting. While its public pipeline data shows activity in oncology and other areas, its stated mission centers on advancing antiviral and antibody treatments, positioning it at the intersection of internal R&D and external service provision.

Custom chemical synthesis, assay development, high-throughput screening (HTS), and drug delivery/formulation expertise.

In CDMO services, Alchem competes with a range of firms from large multinationals (Lonza, Catalent) to smaller niche players. In infectious disease therapeutics, competition is intense from large pharmaceutical companies and well-funded biotechs (e.g., Gilead, Vir Biotechnology, Regeneron). Its hybrid model is somewhat unique but requires excellence in both service delivery and innovative R&D to stand out.